This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Cagrilintide has shown promising weight loss effects in early-stage trials.
Why it matters
These treatments could offer new options for obesity management, addressing a significant public health issue. Understanding their long-term effects is crucial for their successful implementation.
How the study worked
The study summarizes findings from preclinical and early-stage clinical trials of long-acting amylin analogues.
What this study cannot tell us
The study primarily reviews early-stage research, and long-term effects in diverse populations remain unclear.
Read the original research
Long-acting amylin analogues for the management of obesity.
Current opinion in endocrinology, diabetes, and obesity, 29(2), 183-190
Citation
Mathiesen, David S; Bagger, Jonatan I; Knop, Filip K. (2022). Long-acting amylin analogues for the management of obesity.. Current opinion in endocrinology, diabetes, and obesity, 29(2), 183-190. https://doi.org/10.1097/MED.0000000000000716